Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cardioxane in pediatric oncohematology]

V I Kurmashov, I E Gavrilova, S A Maiakova

    Voprosy Onkologii
    |January 1, 1997
    PubMed
    Summary

    Dexrazoxane (JCRF-187) demonstrated good tolerance in pediatric cancer patients receiving anthracycline chemotherapy. This cardioprotective agent showed no adverse effects or interference with cancer treatment efficacy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Appearance and spread of norovirus genotype GII.17 subcluster C2 (Romania-2021 like) in Nizhny Novgorod, Russia, 2021-2023.

    Archives of virology·2025
    Same author

    Unusual BA222-like strains of <i>Rotavirus A</i> (Sedoreoviridae: <i>Rotavirus: Rotavirus A</i>): molecular and genetic analysis based on all genome segments.

    Voprosy virusologii·2024
    Same author

    What are the 100 most cited fungal genera?

    Studies in mycology·2024
    Same author

    Phylogeny, taxonomy, and character evolution in <i>Entoloma</i> subgenus <i>Nolanea</i>.

    Persoonia·2024
    Same author

    Fungal Planet description sheets: 1284-1382.

    Persoonia·2023
    Same author

    Detection and full-genotype determination of rare and reassortant rotavirus A strains in Nizhny Novgorod in the European part of Russia.

    Archives of virology·2023

    Area of Science:

    • Oncology
    • Pharmacology
    • Pediatrics

    Context:

    • Cardioxan (dexrazoxan) is an ethylenediamine tetra-acetic acid analog.
    • Pediatric patients with oncohematological conditions often undergo polychemotherapy.
    • Anthracycline antibiotics are commonly used in pediatric cancer treatment.

    Purpose:

    • To evaluate the tolerance of Cardioxan (dexrazoxan) in pediatric cancer patients.
    • To assess potential side effects of Cardioxan (dexrazoxan) during chemotherapy.
    • To determine if Cardioxan (dexrazoxan) affects the efficacy of cancer treatment.

    Summary:

    • Dexrazoxan was administered to 37 pediatric patients with acute lymphoblastic leukemia, non-lymphoblastic leukemia, non-Hodgkin's lymphoma, and Hodgkin's disease.
    • Patients received polychemotherapy including anthracycline antibiotics concurrently with dexrazoxan.

    Related Experiment Videos

  • No adverse side effects or inhibition of therapeutic effects were observed during the study.

    • Impact:

    • Dexrazoxan appears to be a well-tolerated cardioprotective agent in pediatric cancer patients.
    • The findings suggest dexrazoxan can be safely used with anthracycline-based chemotherapy regimens.
    • This supports the potential use of dexrazoxan to mitigate cardiotoxicity in pediatric oncology.